Loading
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Previous close
$0.8215
+$0.0405 · +5.19%
Regular session · ET · Market data may be delayed.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Day range
Current $0.8215
52-week range
Current $0.8215
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
90
Deep Value
Sentiment
55
Mixed
Risk
75
High Risk
Momentum
28
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Day range
Current $0.8215
52-week range
Current $0.8215
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 80.28M USD | 69.3M USD | 58.45M USD | 41.42M USD | 29.46M USD |
| Cost of goods sold | 25.93M USD | 22.81M USD | 18.34M USD | 14.37M USD | 10.65M USD |
| Gross profit | 54.34M USD | 46.49M USD | 40.11M USD | 27.04M USD | 18.81M USD |
| Research and development | 9.22M USD | 8.81M USD | 9.62M USD | 8.94M USD | 6.74M USD |
| Selling, general, and administrative | 78.88M USD | 79.37M USD | 74.57M USD | 57.11M USD | 41.52M USD |
| Operating expenses | 88.1M USD | 80.6M USD | 84.19M USD | 66.05M USD | 48.26M USD |
| Interest expense | 5.25M USD | 5.29M USD | 5.22M USD | 4.05M USD | 3.6M USD |
| Depreciation and amortization | 1.01M USD | 1.01M USD | 808K USD | 1.19M USD | 535K USD |
| Operating income | −33.76M USD | −34.12M USD | −44.08M USD | −39.01M USD | −29.45M USD |
| Net income | −38.83M USD | −37.84M USD | −46.66M USD | −44.3M USD | −33.28M USD |
Company facts updated Sep 5, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$8.25
904.26% upsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
